GlassScriptPhysician profile
Paul Renzetti
NPI 1598201675
$4,737.40
in general payments reported to CMS, 2019-2025
29 companies · $14.99 in 2025
The $14.99 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,720 · 2022: $2,205 · 2023: $783 · 2024: $14.18 · 2025: $14.99.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $812.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $812.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,455.14 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $475.91 | 2021-2023 | Farxiga, Breztri |
| Amgen INC. | $406.57 | 2021-2022 | |
| Lilly USA, LLC | $295.94 | 2021-2023 | Mounjaro, Jardiance, Emgality |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $289.53 | 2021-2023 | Relistor |
| Otsuka America Pharmaceutical, INC. | $161.19 | 2021-2023 | Rexulti, Abilify Maintena |
| Nestle Healthcare Nutrition INC. | $143.58 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $140.53 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $131.43 | 2021-2023 | Ofev, Jardiance |
| Dexcom, INC. | $127.49 | 2022-2023 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $126.80 | 2021-2023 | |
| Astellas Pharma US INC | $103.54 | 2021-2022 | |
| Amarin Pharma, INC. | $91.47 | 2021 | |
| Novartis Pharmaceuticals Corporation | $90.58 | 2021-2023 | |
| Biohaven Pharmaceuticals, INC. | $77.70 | 2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $71.67 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $70.32 | 2021-2022 | |
| Mylan Specialty L.P. | $64.71 | 2022-2023 | Yupelri |
| Janssen Pharmaceuticals, INC | $62.42 | 2021 | |
| Hikma Pharmaceuticals USA | $61.55 | 2022 | |
| Ironwood Pharmaceuticals, INC | $56.11 | 2022-2023 | Linzess |
| Xeris Pharmaceuticals, INC. | $46.95 | 2022 | |
| Glaxosmithkline, LLC. | $39.98 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $32.38 | 2021 | |
| Lifescan, INC. | $30.29 | 2023 | |
| Theratechnologies INC. | $22.15 | 2021 | |
| Pfizer INC. | $21.16 | 2023 | |
| Lucid Diagnostics INC. | $20.40 | 2022 | |
| Exact Sciences Corporation | $19.91 | 2023 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Renzetti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.